Aptevo Therapeutics Inc. (APVO) — DEF 14A Filings
All DEF 14A filings from Aptevo Therapeutics Inc.. Browse 5 Proxy Statement reports with AI-powered summaries and risk analysis.
DEF 14A Filings (5)
-
Aptevo's Executive Pay Leans on Equity Incentives
— Jul 3, 2025 Risk: medium
Aptevo Therapeutics Inc.'s DEF 14A filing primarily details executive compensation and equity award changes for the fiscal years 2022, 2023, and 2024, rather th -
Aptevo Therapeutics Files Definitive Proxy Statement
— Apr 25, 2025 Risk: low
Aptevo Therapeutics Inc. filed a Definitive Proxy Statement (DEF 14A) on April 25, 2025, for a special meeting of stockholders. The filing concerns the company' -
Aptevo Therapeutics Files Definitive Proxy Statement
— Oct 3, 2024 Risk: low
Aptevo Therapeutics Inc. filed a definitive proxy statement (DEF 14A) on October 3, 2024, for its fiscal year ending December 31, 2024. The filing, related to t -
Aptevo Therapeutics Files 2024 Proxy Statement
— Jul 15, 2024 Risk: low
Aptevo Therapeutics Inc. filed a definitive proxy statement (DEF 14A) on July 15, 2024, for its annual meeting of stockholders scheduled for August 6, 2024. The -
Aptevo Therapeutics Inc. Announces 2024 Annual Meeting of Stockholders on June 7
— Apr 23, 2024 Risk: low
Aptevo Therapeutics Inc. (APVO) filed a Proxy Statement (DEF 14A) with the SEC on April 23, 2024. Aptevo Therapeutics Inc. will hold its 2024 Annual Meeting of
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX